Redeye comments on the preliminary one-year results from the ProTrans-Young trial, announced by Next...
Redeye provides a preview ahead of Sleep Cycles’ Q1 2025 results.
Umida Group AB (”Umida”, ”Koncernen” eller ”Bolaget”) meddelade den 7 april år 2025 att Bolaget har ...
Report out 29 April No major machine deliveries in Q1e Minor est.
Medtech is not exempt from US reciprocal tariffs, unlike Pharma.
Redeye leaves a comment on Curasight following Friday's announcement of a DKK100m rights issue.
On April 4th, STENOCARE announced that the innovative ASTRUM 10-10 has obtained for approval for rei...
The Board of Directors proposes an additional one-time extra dividend of SEK0.
Redeye provides a research note on Faron Pharmaceuticals following the announcement of a convertible...
Report due 6 May 2025 Q1e net sales of SEK 209m, EBITA of SEK 34m We reiterate our fair value range ...
Redeye is pleased to note that Smart Eye announced two new design wins worth SEK200m today with an u...
Lipigon har vidtagit åtgärden för att skynda på rekryteringen till bolagets fas 2-studie som dragit ...
Redeye initiates coverage of Tradedoubler, a leading digital network within affiliate and influencer...
Redeye gives a short comment on the positive preliminary outcome of Saniona’s TO4 warrant program.
Redeye comments on the intriguing news that a newly published article in Nature highlights the poten...
Redeye is a bit surprised to hear that CEO Roland Kasper is about to be replaced.
Den 1 april 2025 meddelade AcuCort (”AcuCort” eller ”Bolaget”) att Bolaget mottagit en ny order på Z...
Redeye leaves a comment following today’s announcement of a rights issue of approximately SEK35.
Q1e: Flat organic sales growth, 5.3% adj. EBITA margin Expect Sweden to weigh on growth, awaiting AD...
Redeye comments on Maximum Entertainment’s announcement regarding notice of default on its US loan w...
